Gilead Sciences stock drops 2.59% as collaboration with WHO on kala-azar elimination renewed, Gilead Sciences

Traders Union
All News
Companies
Gilead Sciences drops 2.59% today

Highlights

Gilead Sciences is trading below key short- and medium-term averages, facing downside pressure with limited support near $128.71.
Momentum indicators signal prevailing bearish sentiment, with oversold readings and a lack of clear trend driving sustained weakness.
Price is expected to consolidate within $124.50–$132.80, with a strong probability of further decline unless resistance above $132.57 is reclaimed.

Downside pressure as price hovers near critical support and resistance

Gilead Sciences (GILD) is trading at $127.71, well below the 20-day ($132.79) and 50-day ($134.90) simple moving averages, indicating near-term and medium-term downside pressure. The price sits just above the 200-day SMA ($128.71), providing a key longer-term support zone, while the Ichimoku Kijun at $132.57 acts as immediate resistance. Near-term support appears at the 200-day SMA ($128.71), with key support at the 52-week low ($104.46). Immediate resistance clusters at the Kijun ($132.57), with key resistance at the 50-day SMA ($134.90).

Prevailing seller momentum as trend signals weaken and volatility spikes

Momentum readings confirm the prevailing weakness: MACD on D1 signals strong sell, while ADX on D1 (10.95) reflects a trendless, indecisive environment. RSI (44.42) and CCI (-43.03) remain in lower-neutral to mildly oversold territory, with Stoch RSI (27.36) leaning towards oversold and BBP showing dominant seller pressure. Awesome Oscillator is neutral, not adding to directional conviction. In today’s session, GILD has dropped 2.59%, extending a weekly loss of 4.99% from the previous close at $134.43 and placing the stock at the very bottom of its weekly range. Weekly volatility stands at 5.08%, confirming a sharp, steady decline from the recent high.

Further declines likely as bearish bias outweighs divergent weekly signals

Looking ahead, the expected range for the coming week is $124.50 to $132.80, keeping the price well above the 52-week low ($104.46) but distant from the 52-week high ($157.29). The probability of further decline is high (more than 80%) based on only one supportive signal (MA-50 W1), while RSI W1 and ADX W1 remain neutral-to-bearish and MACD W1 is bullish, introducing some divergence but overall biasing to the downside. Baseline scenario: price consolidates between near-term support and resistance as sellers dominate. Bullish scenario: a break above $132.57–$134.90 could trigger a relief rally toward higher resistance. Bearish scenario: sustained trading below $128.71 risks a move toward the lower $120s.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Gilead Sciences was consolidating near resistance, with a bullish bias prevailing and potential for renewed upside momentum. Building on this analysis, investors should now monitor for confirmation of a breakout or a reversal in trend, as either scenario could redefine near-term trading opportunities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.